Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Pfizer $PFE and Gilead $GILD are joining hands on a new combo program that will tie the CAR-T star Yescarta with an early-stage drug that has been bouncing around the clinic for the last few years.
Pfizer’s utomilumab (PF-05082566) is also in combo studies with Keytruda and Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. It’s a 4-1BB agonist, which researchers believe could prove a key player in spurring an amped up T cell attack on cancer cells among patients with large B-cell lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.